Vor Biopharma

Vor Biopharma

VOR· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -41.1% in FY2025

Jean-Paul Kress is the CEO of Vor Biopharma and was paid $65.0M in FY2025 (Dec).

Pay$100 in the stock at the end of FY24 → $59
CEO pay is from each Vor Biopharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives4

See all
  1. 1Jean-Paul KressFY2025
  2. 2Sandesh MahatmeFY2025
  3. 3Qing ZurawFY2025
  4. 4Robert AngFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Vor Biopharma paid its 4 named executives $119.6M in total in FY2025 (Dec). CEO Jean-Paul Kress was paid $65.0M of that.

Name
Jean-Paul KressPresident, Chief Executive Officer and ChairmanNot disclosedNot disclosed
Sandesh MahatmeChief Financial OfficerNot disclosedNot disclosed
Qing ZurawFormer Chief Development OfficerNot disclosedNot disclosed
Robert AngFormer President and Chief Executive OfficerNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for Vor Biopharma. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Board1

See all
  • Fouad NamouniDirector · 1 yr on the boardIndependentCompensation, Nominating and Corporate Governance—Paid as an executive

The board of the latest proxy (FY2025).

Activity

Filings6

See all
Proxy statementDEF 14AApr 27, 2026FY2025
Annual report10-KMar 30, 2026FY2025
Proxy statementDEF 14AApr 8, 2025FY2024
Annual report10-KMar 20, 2025FY2024
Proxy statementDEF 14AApr 9, 2024FY2023
Annual report10-KMar 20, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data